A Molecular Diagnostics Company
Making Early Cancer Detection the New Standard of Primary Care
Our Mission
For heart disease, thyroid function and diabetes… frequent, recurrent, sequential monitoring and screening are standard of primary care in asymptomatic populations.
Our Science
Find out how we’re unlocking frequent, recurring monitoring for early cancer signal as the new standard of primary care.
More accurate & reliable
More cost effective
fully scalable
significant societal impact
Our Social Impact
Latest News
New Peer-Reviewed Publications
August 27, 2026
Two peer-reviewed publications now describe Acuamark's sequencing-free, blood-based platform for early colorectal cancer detection – from analytical development through initial clinical evaluation.
In the clinical publication, the top-performing models achieved 92% sensitivity at 97% specificity on a qPCR readout, in a validation subset spanning Stages I–IV. Early-stage performance was strong, to be confirmed in larger cohorts.
The companion publication describes the underlying 40-marker enzymatic cfDNA methylation assay using qPCR and dPCR readouts.
Together, the publications support Acuamark's approach to both requirements of early cancer detection: detecting faint signals in early-stage disease and making that capability broadly deployable.
Read the full announcement and access both publications:
Acuamark's assays are investigational and are not approved for clinical use.
#EarlyCancerDetection #ColorectalCancer #LiquidBiopsy #MolecularDiagnostics #qPCR
AcuamarkDx Welcomes Two New Board Members
December 5, 2024
AcuamarkDx is pleased to announce the addition of Tim Gordon and Chiara Gabbi, MD, PhD, to ourboard of directors. Their expertise in financial strategy and clinical research will help guide us as we advance our groundbreaking early cancer detection technology through clinical development and toward commercialization.
Acuamark at LSI Europe 2024
November 5, 2024
AcuamarkDx's Co-Founder and CEO Bernard Peperstraete recently presented to a full room at #LSIEurope24.
Bernard highlighted Acuamark's groundbreaking advancements in early cancer detection technology and shared insights into our innovative approach— including proprietary qPCR and machine learning-driven assays, which achieve high sensitivity and specificity in detecting early-stage cancer.
Watch the presentation here:
